Casma Therapeutics utilizes its PHLYT™ platform to enhance autophagic degradation of damaged cellular components, targeting diseases that existing therapies cannot effectively address. By reprogramming the natural cellular process of autophagy, the company aims to improve patient outcomes in conditions resistant to current drug treatments.
Funding
$154.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AVAVECECEA+4Founders
Product
Problem
Many diseases are caused by the accumulation of damaged or dysfunctional components within cells, which existing therapies often fail to address effectively. Current treatments may not be able to target these intracellular components for degradation and removal, leading to disease progression.
Solution
Casma Therapeutics is developing a platform, called PHLYT™, to selectively enhance autophagy, the natural cellular process of degrading and removing damaged components. By reprogramming autophagy, Casma aims to target and eliminate disease-causing agents within cells, independent of their size or complexity. This approach seeks to improve patient outcomes in diseases that are resistant to current drug treatments by enhancing the cell's natural quality control system. The PHLYT™ platform initiates target-specific autophagic degradation of new disease targets.
Target Audience
The primary target audience includes patients suffering from diseases caused by the accumulation of damaged cellular components, as well as researchers and clinicians seeking new therapeutic approaches for these conditions.
Features
- PHLYT™ (Phagosome-Lysosome Targeting) platform for initiating target-specific autophagy
- Ability to degrade disease targets independent of size or complexity
- Focus on enhancing the degradative capacity of autophagy
- Aims to eliminate diseases that current drugs have failed to target